New drug combo aims to shrink rare nerve tumors before surgery
NCT ID NCT06693284
First seen Jan 08, 2026 · Last updated May 19, 2026 · Updated 20 times
Summary
This early-phase trial tests whether a 28-day course of two oral drugs (mirdametinib and vorinostat) can safely shrink or change a rare, aggressive nerve sheath tumor in people with neurofibromatosis type 1 (NF1). Up to 8 participants aged 12 and older will receive the drugs before their usual treatment (radiation and surgery). The study checks for side effects and looks at tumor changes through scans and biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MALIGNANT PERIPHERAL NERVE SHEATH TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55414, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.